Targeting Cancer Cachexia with Soluble Epoxide Hydrolase Inhibitors

Abstract

Researchers at the University of California, Davis have developed a therapeutic approach to prevent and treat cancer cachexia by inhibiting soluble epoxide hydrolase, promoting resolution of systemic inflammation, mitigating muscle wasting, and improving survival outcomes in preclinical models without inducing toxicity or immunosuppression.

Full Description

This technology involves the use of a soluble epoxide hydrolase inhibitor (sEHI) to treat cancer cachexia by targeting systemic inflammation and pro-inflammatory cytokines. Through pharmacological inhibition of sEH, this approach aims to harness the anti-inflammatory properties of epoxyeicosatrienoic acids (EETs) to mitigate muscle wasting and hyperinflammation in cancer cachexia. Preclinical models have demonstrated increased survival rates, reduced inflammation markers, and normalization of immune cell populations with sEHI treatment.

Applications

• Pharmaceutical treatment for cancer cachexia in patients suffering from various types of cancer. 
• Complementary therapy in oncology to improve patient outcomes and quality of life. 
• Potential for development into a standard care regimen for managing cachexia symptoms in cancer patients.

Features/Benefits

• First-of-its-kind approach targeting the host immune response for cancer cachexia treatment. 
• Improves survival rates in murine cancer cachexia models without inducing toxicity or immunosuppression. 
• Reduces expression of pro-inflammatory markers and restores balance to immune cell populations. 
• Potential to significantly improve quality of life and survival for cancer patients affected by cachexia. 
• Provides effective treatments for cancer cachexia, a major cause of morbidity and mortality in cancer patients. 
• Treats systemic inflammation and muscle wasting associated with cancer cachexia. 
• Provides a treatment that can target the underlying mechanisms of cancer cachexia without causing adverse effects.

Patent Status

Patent Pending